AngioDynamics (ANGO) Lowered to “Sell” at BidaskClub

BidaskClub lowered shares of AngioDynamics (NASDAQ:ANGO) from a hold rating to a sell rating in a report released on Saturday morning.

Other research analysts have also recently issued research reports about the stock. KeyCorp restated a hold rating on shares of AngioDynamics in a report on Friday, September 29th. Zacks Investment Research upgraded shares of AngioDynamics from a hold rating to a buy rating and set a $19.00 price objective for the company in a report on Tuesday, October 3rd. Craig Hallum cut shares of AngioDynamics from a buy rating to a hold rating in a report on Friday, January 5th. TheStreet cut shares of AngioDynamics from a b- rating to a c rating in a report on Tuesday, January 2nd. Finally, Canaccord Genuity restated a hold rating and set a $17.00 price objective on shares of AngioDynamics in a report on Sunday, October 8th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $18.40.

AngioDynamics (ANGO) opened at $16.40 on Friday. The stock has a market cap of $611.32, a P/E ratio of -60.74, a P/E/G ratio of 1.57 and a beta of 1.04. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.65 and a current ratio of 2.56. AngioDynamics has a 1-year low of $14.80 and a 1-year high of $18.85.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Thursday, January 4th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.16. The firm had revenue of $86.70 million during the quarter, compared to analysts’ expectations of $88.15 million. AngioDynamics had a negative net margin of 2.27% and a positive return on equity of 4.63%. The business’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.19 earnings per share. equities analysts forecast that AngioDynamics will post 0.68 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of AngioDynamics in the third quarter valued at approximately $143,000. Acrospire Investment Management LLC boosted its holdings in shares of AngioDynamics by 3.7% in the second quarter. Acrospire Investment Management LLC now owns 8,915 shares of the medical instruments supplier’s stock valued at $145,000 after buying an additional 317 shares during the period. Trexquant Investment LP acquired a new position in shares of AngioDynamics in the third quarter valued at approximately $175,000. Teachers Retirement System of The State of Kentucky boosted its holdings in shares of AngioDynamics by 54.9% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 11,000 shares of the medical instruments supplier’s stock valued at $178,000 after buying an additional 3,900 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its holdings in shares of AngioDynamics by 49.3% in the second quarter. BNP Paribas Arbitrage SA now owns 14,135 shares of the medical instruments supplier’s stock valued at $229,000 after buying an additional 4,668 shares during the period. Institutional investors own 95.23% of the company’s stock.

WARNING: “AngioDynamics (ANGO) Lowered to “Sell” at BidaskClub” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.com-unik.info/2018/01/10/angiodynamics-ango-lowered-to-sell-at-bidaskclub.html.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

What are top analysts saying about AngioDynamics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AngioDynamics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit